Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 48 min 9 sec ago

Corvus Pharmaceuticals Names Jason V. Coloma to Newly Created Post of Chief Business Officer

Wed, 06/29/2016 - 15:35
BURLINGAME, Calif., June 29, 2016 -- (Healthcare Sales & Marketing Network) -- Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announ...
Biopharmaceuticals, Oncology, Personnel
Corvus Pharmaceuticals, immunotherapy

Biostage Files for FDA Orphan Drug Designation for Cellspan(TM) Esophageal Implant

Wed, 06/29/2016 - 13:39
Orphan Drug Designation Provides Range of Benefits Including Seven-Year Market Exclusivity HOLLISTON, Mass., June 29, 2016 -- (Healthcare Sales & Marketing Network) -- Biostage, Inc. (BSTG), a biotechnology company developing bioengineered organ implan...
Regenerative Medicine, FDA
Biostage, bioengineered organ, Cellspan, Esophageal Implant

AntriaBio Announces $12 Million Private Placement

Wed, 06/29/2016 - 13:31
LOUISVILLE, CO--(Healthcare Sales & Marketing Network) - AntriaBio, Inc. ("AntriaBio" or the "Company") (ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it has successf...
Biopharmaceuticals, Venture Capital
AntriaBio

AbbVie Announces Fourth Breakthrough Therapy Designation Granted by the U.S. Food and Drug Administration (FDA) for Ibrutinib (IMBRUVICA(R)) for Chronic Graft-Versus-Host-Disease (cGVHD), a Rare Condition with Limited Treatment Options

Wed, 06/29/2016 - 13:24
FDA also granted ibrutinib Orphan Drug Designation for this condition. There are currently no therapies specifically approved for cGVHD, a severe and potentially life-threatening condition in which transplanted cells from donor attack the patient's body ...
Biopharmaceuticals
AbbVie, ibrutinib, IMBRUVICA, cGVHD

EnteroMedics Highlights Recent Patient Success with vBloc(R) Therapy in Combination with vBloc(R) Achieve Program

Wed, 06/29/2016 - 13:16
ST. PAUL, Minn., June 29, 2016 -- (Healthcare Sales & Marketing Network) -- EnteroMedics Inc. (ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announce...
Devices
EnteroMedics, neuroblocking, vBloc , Neurometabolic Therapy

FDA Advisory Committee recommends approval of Jardiance(R) (empagliflozin) for cardiovascular indication in 12-11 vote

Wed, 06/29/2016 - 13:03
Endocrinologic and Metabolic Drugs Advisory Committee votes in favor of CV mortality benefit for JARDIANCE for adults with type 2 diabetes RIDGEFIELD, Conn. and INDIANAPOLIS, June 28, 2016 -- (Healthcare Sales & Marketing Network) -- A U.S. Food and Dr...
Biopharmaceuticals, Endocrinology, Cardiology, FDA
Eli Lilly, Boehringer Ingelheim, Jardiance, empagliflozin

GORE(R) VIABAHN(R) Endoprosthesis Found to Provide Superior Patency and Reduced Interventions Versus Balloon Angioplasty Alone for Challenging AV Access Cases

Tue, 06/28/2016 - 17:58
New data from Gore REVISE Clinical Study published online in Journal of Vascular Surgery illustrate role device can play in maintaining and salvaging failing dialysis circuits FLAGSTAFF, Ariz.--(Healthcare Sales & Marketing Network)--W. L. Gore & Associ...
Devices, Interventional
W. L. Gore, VIABAHN, Endoprosthesis

iSTAR Medical Strengthens Board With Two Senior Appointments

Tue, 06/28/2016 - 13:23
Martin Wax, M.D. and Marc Nolet de Brauwere Appointed to Board of Directors WAVRE, Belgium, June 28, 2016 -- (Healthcare Sales & Marketing Network) -- iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the treat...
Devices, Ophthalmology, Personnel
iSTAR Medical, glaucoma

FDA Grants Priority Review for Genentech’s OCREVUS(TM) (ocrelizumab) Biologics License Application

Tue, 06/28/2016 - 13:16
Biologics License Application (BLA) acceptance follows European Medicines Agency’s (EMA’s) validation of the Marketing Authorization Application (MAA) for OCREVUS in relapsing and primary progressive multiple sclerosis (MS) OCREVUS is the first investig...
Biopharmaceuticals, Neurology, FDA
Genentech, OCREVUS, ocrelizumab, multiple sclerosis

Pfizer Advances Biosimilars Leadership with Investment in a New World-Class Global Biotechnology Center in China

Tue, 06/28/2016 - 13:11
Pfizer’s state-of-the-art facility will foster the continued development of the biotechnology industry in China, further supporting National healthcare reforms NEW YORK & HANGZHOU, China--(Healthcare Sales & Marketing Network)--Pfizer Inc. today announc...
Biopharmaceuticals
Pfizer, biosimilar

Halt Medical, Inc. Announces The First Acquisition Of Acessa Guidance System

Tue, 06/28/2016 - 13:04
BRENTWOOD, Calif., June 27, 2016 -- (Healthcare Sales & Marketing Network) -- Halt Medical, Inc. announced today that Trinity Park Surgery Center, Arlington, TX, is the first facility in the United States to acquire the Acessa® Guidance System1. &q...
Devices
Halt Medical, Acessa Guidance System, uterine fibroids, radiofrequency ablation

GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex(R) (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

Mon, 06/27/2016 - 14:13
Primary endpoint achieved with high statistical significance (p=0.0135) showing that Epidiolex treatment reduces drop seizures compared to placebo Today’s LGS data follows successful Phase 3 trial in Dravet syndrome announced in March 2016 Company to...
Biopharmaceuticals
GW Pharmaceuticals, Epidiolex, cannabinoid, Lennox-Gastaut

Accuray Receives 510(k) FDA Clearance for the Radixact(TM) Image-Guided Radiation Therapy Platform and Integrated Software

Mon, 06/27/2016 - 13:44
Next Generation "Smart" System Enables Clinicians to Provide Highly Precise Treatment, Efficiently, for More Patients, Every Day SUNNYVALE, Calif., June 27, 2016 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (ARAY) announc...
Devices, Oncology, FDA
Accuray, Radixact, Accuray Precision, radiotherapy

Merck Receives CHMP Positive Opinion for KEYTRUDA(R) (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Mon, 06/27/2016 - 13:37
Opinion Based on Data from KEYNOTE-010, Which Showed Superior Overall Survival Compared to Chemotherapy in Previously-Treated Patients Whose Tumors Express PD-L1 KENILWORTH, N.J.--(Healthcare Sales & Marketing Network)--Merck (MRK), known as MSD outside...
Biopharmaceuticals, Oncology, Regulatory
Merck, KEYTRUDA, pembrolizumab, anti-PD-1 therapy, NSCLC

Avita Medical Awarded US$7.96M in BARDA Extension Deal

Mon, 06/27/2016 - 13:18
Additional non-dilutive funds to accelerate US market approval and product launch Support aims to increase familiarity/acceptance in US Burn Centers, demonstrate economic benefits and increase acceptance of ReCell® in US Burn Centers Funds will b...
Regenerative Medicine, Venture Capital
Avita Medical, ReCell

Medigus’ MUSE(TM) Continues to Gain Clinical Adoption in the U.S.

Fri, 06/24/2016 - 14:52
Innovative technology allows physicians to perform transoral fundoplication for effective, long-term treatment of acid reflux and improve patients’ GERD-related quality of life OMER, Israel, June 24, 2016 -- (Healthcare Sales & Marketing Network) -- Med...
Devices, Surgery, Gastroenterology
Medigus, Ultrasonic Surgical Endostapler, transoral fundoplication, GERD

Pfizer Completes Acquisition of Anacor

Fri, 06/24/2016 - 14:47
Tender offer for all of the outstanding shares of Anacor common stock expired as scheduled immediately after 11:59 p.m., New York City time, on June 23, 2016 Pfizer and Anacor begin joint operations on June 24, 2016 NEW YORK--(Healthcare Sales & Mar...
Biopharmaceuticals, Mergers & Acquisitions
Pfizer, Anacor Pharmaceuticals

Allergan Announces FDA Approval of Supplemental New Drug Application (sNDA) for AVYCAZ(R) (ceftazidime and avibactam)

Thu, 06/23/2016 - 14:24
Label now includes Phase 3 clinical data evaluating the safety and efficacy of AVYCAZ (in combination with metronidazole) in patients with complicated intra-abdominal infections (cIAI) DUBLIN, June 23, 2016 -- (Healthcare Sales & Marketing Network) -- ...
Biopharmaceuticals, FDA
Allergan, AVYCAZ, ceftazidime, avibactam, cIAI

St. Jude Medical Expands Its Heart Failure Portfolio with SyncAV CRT Technology, Providing Physicians Another Option for Managing Patients Not Responsive to Other Therapies

Thu, 06/23/2016 - 14:14
Adding SyncAV™ CRT technology to the company’s comprehensive heart failure offerings provides further advantages to the St. Jude Medical portfolio to support physicians seeking new treatment options for heart failure patients ST. PAUL, Minn.--(Healthcar...
Devices, Cardiology, Regulatory, Product Launch
St. Jude Medical, SyncAV CRT, MultiPoint Pacing, cardiac resynchronization

HeartFlow Introduces Next Generation Platform

Thu, 06/23/2016 - 14:05
REDWOOD CITY, Calif.--(Healthcare Sales & Marketing Network)--HeartFlow, Inc., a personalized medical technology company seeking to transform the way cardiovascular disease is diagnosed and treated, announced today that it is launching its next generation ...
Devices, Personalized Medicine, Cardiology, Product Launch
HeartFlow, FFRct

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong